Comprehensive mutation screening for 10 genes in Chinese patients suffering very early onset inflammatory bowel disease

Abstract

AIM: To perform sequencing analysis in patients with very early-onset inflammatory bowel disease (VEO-IBD) to determine the genetic basis for VEO-IBD in Chinese pediatric patients.

METHODS: A total of 13 Chinese pediatric patients with VEO-IBD were diagnosed from May 2012 and August 2014. The relevant clinical characteristics of these patients were analyzed. Then DNA in the peripheral blood from patients was extracted. Next generation sequencing (NGS) based on an Illumina-Miseq platform was used to analyze the exons in the coding regions of 10 candidate genes: IL-10, IL-10RA, IL-10RB, NOD2, FUT2, IL23R, GPR35, GPR65, TNFSF15, and ADAM30. The Sanger sequencing was used to verify the variations detected in NGS.

RESULTS: Out of the 13 pediatric patients, ten were diagnosed with Crohn’s disease, and three diagnosed with ulcerative colitis. Mutations in IL-10RA and IL-10RB were detected in five patients. There were four patients who had single nucleotide polymorphisms associated with IBD. Two patients had IL-10RA and FUT2 polymorphisms, and two patients had IL-10RB and FUT2 polymorphisms. Gene variations were not found in the rest four patients. Children with mutations had lower percentile body weight (1.0% vs 27.5%, P = 0.002) and hemoglobin (87.4 g/L vs 108.5 g/L, P = 0.040) when compared with children without mutations. Although the age of onset was earlier, height was shorter, and the response to treatment was poorer in the mutation group, there was no significant difference in these factors between groups.

CONCLUSION: IL-10RA and IL-10RB mutations are common in Chinese children with VEO-IBD. Patients with mutations have an earlier disease onset, lower body weight and hemoglobin, and poorer prognosis.

Core tip: In this small-sample size study, we performed next generation sequencing for 10 candidate genes in Chinese pediatric patients with very early onset inflammatory bowel disease. We found that IL-10RA and IL-10RB mutations were common. There were five patients harbouring mutations in these two genes and accounted for 38.5% of all samples. Besides, there were four patients who had single nucleotide polymorphisms associated with inflammatory bowel disease. Pediatric patients with mutations had an earlier disease onset, lower body weight, markedly lower hemoglobin, and poorer prognosis.

INTRODUCTION

Inflammatory bowel disease (IBD) is a chronic and recurrent gastrointestinal inflammatory disease in children. Based on clinical characteristics, laboratory tests, and endoscopic and pathological presentations, IBD can be subdivided into Crohn’s disease (CD), ulcerative colitis (UC), and IBD-unclassified (IBD-U)[1]. Our previous study showed that the annual incidence of IBD in the 0- to 14-year age group of Shanghai residents steadily increased from 2000 to 2010[2]. Although pediatric IBD mainly occurs in adolescence[2], approximately 15% of IBD pediatric patients have very early-onset IBD (VEO-IBD) that begins before 6 years of age, and 1% of children develop this disease before reaching 1 year of age[3,4]. The majority of VEO-IBD cases have clinical characteristics that are distinct from those of classic IBD with adult and adolescent onset. VEO-IBD has more severe clinical symptoms, resistance to a variety of immunosuppressive therapies, and a poor prognosis after conventional treatments. Some scholars even consider VEO-IBD to be a completely different disease from classic IBD[5].

Previous studies suggested that persistent intestinal immune dysfunction in a genetically susceptible individual exposed to adverse environmental factors is an important mechanism for IBD development. Genome-wide association studies (GWAS) have discovered a total of 163 loci associated with the risk for IBD development[6]. However, disease onset at an early stage of life suggests a leading role for rare gene variations in VEO-IBD patients, especially in children with a disease onset before the age of 1 year. These low frequency mutations are difficult to detect using GWAS. Next generation sequencing technology allows for the high-throughput sequencing of exons in a series of genes concurrently; therefore, rare gene variations can be discovered[7]. Since Glocker et al[8] first discovered in 2009 that mutations in genes encoding the α subunit (IL-10R1, encoding gene IL-10RA) and the β subunit (IL-10R2, encoding gene IL-10RB) of the interleukin-10 (IL-10) receptor could induce VEO-IBD development, a few studies have continuously discovered mutations in genes encoding IL-10R1, IL-10R2, and IL-10[5,9-12]. However, current reports are limited, and the majority of studies are small-size case studies. Reports on the Han Chinese population are scarcer[13,14].

This study used the Illumina-Miseq platform to sequence candidate genes in Han Chinese children diagnosed with VEO-IBD. The candidate genes included genes involved in the IL-10 signaling pathway, such as IL-10, IL-10RA, and IL-10RB, and genes highly associated with the development of CD in previous studies, including NOD2, FUT2, IL-23R, GPR35, GPR65, TNFSF15, and ADAM30. This study furthers our understanding of the genetic factors associated with VEO-IBD development in Han Chinese children.

MATERIALS AND METHODS

Patient consent and ethic committee approval

Verbal and written consent was obtained from the parents of all of children included this study. Ethic committee approval for the study was granted by Institutional Review Boards of Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine.

Study subjects

A total of 13 pediatric patients with repeated diarrhea, mucus and bloody stool, or abdominal pain who were diagnosed by laboratory tests and digestive endoscopy with VEO-IBD in the Pediatric Department of Ruijin Hospital of Shanghai Jiao Tong University School of Medicine between May 2012 and August 2014 were included in this study. All of the patients were Han Chinese. VEO-IBD was defined as IBD onset before the age of 6 years, and a disease onset before 2 years of age was called infantile-onset IBD[15,16]. The clinical characteristics of these pediatric patients, including gender, age of disease onset, body height, body weight, family history, clinical symptoms, complications, major laboratory examinations, endoscopic presentations, and therapeutic effects, were retrospectively analyzed.

Laboratory and digestive endoscopic examinations

Relevant laboratory examinations, including complete blood count (CBC), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), tumor necrosis factor α (TNF-α) level, immunoglobulins G, A, M, and E, vitamin D, human Immunodeficiency virus (HIV) and human cytomegalovirus (CMV) antibody detection in serum, T lymphocyte flow cytometry sorting, stool parasite tests, stool culture, and stool Clostridium difficile toxin detection, were performed when the patients were admitted to the hospital. Common infectious diseases and primary immunodeficiency diseases were excluded.

All patients received a colonoscopy under general anesthesia. A biopsy of the colonic mucosa under endoscopy was performed for pathological examination.

Illumina-Miseq platform sequencing

Genomic DNA extraction: After obtaining verbal and written informed consent from the patients’ parents, genomic DNA in the peripheral blood from 13 pediatric patients was extracted using a FlexiGene DNA Kit (Qiagen Inc., Germany). Another 100 copies of DNA extracted from patients suffering from idiopathic short stature (ISS) in previous research were used to test frequency of mutant sites which were newly detected in our study.

Multiplex PCR primer design: Based on the stability of the Illumina-Miseq experiment and the operability of subsequent steps, the length requirement of target fragments for sequencing was < 400 bp. If the length of an exon was longer than 400 bp, an additional pair of primers was designed with overlapping bases of adjacent fragments. To avoid a high number of non-target fragment products, primers were grouped and suspended in a primer mix before the multiplex PCR was performed. The concentration of each primer in the primer mix was 10 mmol/L. The basic requirement for grouping was the lack of matching sequences between two of the amplified products. Oligo 7 software was used to design primers for exons of the encoding region of the 10 candidate genes: IL-10, IL-10RA, IL-10RB, NOD2, FUT2, IL23R, GPR35, GPR65, TNFSF15, and ADAM30. A total of 86 pairs of primers were designed. The sequences are shown in supplementary Table 1.

Multiplex PCR amplification of candidate genes: A Qiagen Multiple PCR Kit was used in this study. The PCR amplification reaction system had a total volume of 21 μL, including 4 μL of ddH₂O, 2 μL of Q-solution (5 ×), 4 μL of 10 mmol/L primer mix, 10 μL of buffer mix, and 1 μL of the DNA template (20 ng/μL). The reaction procedure consisted of pre-denaturation at 94 °C for 15 min, denaturation at 94 °C for 40 s, annealing at 63 °C for 1 min, and extension at 72 °C for 40 s. After each cycle, the annealing temperature was reduced by 0.5 °C for 10 cycles until the annealing temperature reached 58 °C. Next, the amplification was continued for 30 cycles with a constant annealing temperature of 58 °C. The final extension at 72 °C lasted for 10 min. The PCR products were stained with 100 × GelRed and subjected to 1% agarose electrophoresis (120 V for 60 min).

The purified multiplex PCR products were sent to Shanghai South Gene Technology Co., Ltd. for sequencing analysis with the Illumina-Miseq platform. After sequencing, the nucleotide sequence information was compared with the standard gene sequences available in GenBank. The obtained gene mutation sites were compared with information in the dbSNP, HGMD, and OMIM databases to determine if the mutations had been previously reported.

To confirm the accuracy of the results, the corresponding gene sequences for the mutations discovered using the Illumina-Miseq platform were sequenced again using the Sanger sequencing method.

The newly discovered gene variation sites were analyzed to predict their influence on protein functions using two online databases: SIFT (http:// http://sift.jcvi.org/) and PolyPhen 2 (http://genetics.bwh.harvard.edu/pph2/).

Statistical analysis

According to the sequencing results, the 13 pediatric patients were divided into two groups. The patients who harboured pathogenic mutations were in group 1. Those without pathogenic mutations (including presence of polymorphisms only or wild type) were in group 2. The differences in diagnosis, age of disease onset, growth indicators (percentiles of body weight and height were calculated according to WHO standards), complications (perianal diseases and recurrent infection), and therapeutic effects among all groups were compared. Because the sample size was small, quantitative and ranked ordinal data were subjected to nonparametric statistics. The Mann-Whitney Test was performed, and the difference was statistically analyzed using exact probability. SPSS13.0 for Windows software was used for the statistical analysis. P < 0.05 indicated a significant difference.

RESULTS

Genotyping in VEO-IBD patients

IL-10RA, IL-10RB, and IL-10 mutations: IL-10RA mutations were detected in four patients, an IL-10RB mutation was detected in one patient, and an IL-10 mutation was not detected in any of the 13 patients.

The detected IL-10RA mutations were all in exon 3: c.A191G (p.Y64C), c.T299G (p.V100G), c.C301T (p.R101W), and c.G350A (rs199989396) (p.R117H). The p.R101W mutation was the most common and was detected in three patients (patients 1-3). The other mutations were detected in only one patient. Patient 1 had a homozygous mutation, patients 2 and 3 had compound mutations, and patient 4 had a heterozygous mutation (Table 1 and Figure 1).

Table 1.

Genotypes of 13 patients diagnosed with very early-onset inflammatory bowel disease

Patient	Gene	Variation	Homo/Heterozygote	Function defect
1	IL-10RA	p.R101W	Homozygote	Yes
2	IL-10RA	p.R101W	Compound heterozygote	Yes
		p.V100G (novel mutation)		Pathogenic supporting by Polyphen 2 and SIFT
3	IL-10RA	p.R101W	Compound heterozygote	Yes
		p.Y64C (novel mutation)		Pathogenic supporting by Polyphen 2 and SIFT
4	IL-10RA	p.R117H (rs199989396)	Heterozygote	Yes
	NOD2	p.R703C (rs5743277)	Heterozygote	Susceptibility to CD recorded in HGMD
	FUT2	p.I140F (rs1047781)	Heterozygote	Susceptibility to CD in Chinese population reported by Hu et al[31]
5	IL-10RB	p.K47E (rs2834167)	Homozygote	SNP in a VEO-UC child reported by Galatola et al[29]
		p.E141K (rs387907326)	Heterozygote	Pathogenic supporting by Polyphen 2 and SIFT
	IL-10RA	p.P115P (rs22280554)	Homozygote	Susceptibility to VEO-IBD reported by Moran et al[30]
		p.I224V (rs22280555)	Homozygote
	FUT2	p.I140F (rs1047781)	Heterozygote	Susceptibility to CD in Chinese population reported by Hu et al[31]
6	IL-10RA	p.P115P (rs22280554)	Homozygote	Susceptibility to VEO-IBD reported by Moran et al[30]
		p.I224V (rs22280555)	Homozygote
	FUT2	p.I140F (rs1047781)	Homozygote	Susceptibility to CD in Chinese population reported by Hu et al[31]
7	IL-10RA	p.P115P (rs22280554)	Homozygote	Susceptibility to VEO-IBD reported by Moran et al[30]
		p.I224V (rs22280555)	Homozygote
	FUT2	p.I140F (rs1047781)	Heterozygote	Susceptibility to CD in Chinese population reported by Hu et al[31]
8	IL-10RB	p.K47E (rs2834167)	Homozygote	SNP in a VEO-UC child reported by Galatola et al[29]
	FUT2	p.I140F (rs1047781)	Heterozygote	Susceptibility to CD in Chinese population reported by Hu et al[31]
9	IL-10RB	p.K47E (rs2834167)	Heterozygote	SNP in a VEO-UC child reported by Galatola et al[29]
	FUT2	p.I140F (rs1047781)	Heterozygote	Susceptibility to CD in Chinese population reported by Hu et al[31]

Patients 10, 11, 12 and 13 were wild types in all these genes. CD: Crohn's disease; UC: Ulcerative colitis; VEO-IBD: Very early-onset inflammatory bowel disease; VEO-UC: Very early-onset ulcerative colitis; SNP: Single nucleotide polymorphism; HGMD: The Human Gene Mutation Database (http://www.hgmd.cf.ac.uk/ac/index.php).

Figure 1.

Causative mutations in IL-10RA (A-D) or IL-10RB (E). A: Patient 1, c.C301T, p.R101W, homozygote; B: Patient 2, c.T299G, p.V100G and c. C301T, p.R101W, compound heterozygote; C: Patient 3, c.A191G, p.Y64C and c. C301T, p.R101W, compound heterozygote; D: Patient 4, c.G35A, p.R117H (rs199989396), heterozygote; E: Patient 5, c.G421A, p.E141K (rs387907326), heterozygote.

Among detected IL-10RA mutations, p.Y64C and p.V100G were new mutations that were predicted to be deleterious by SIFT and Polyphen 2. These novel mutant sites were not found in 100 ISS children. The other two mutations had been confirmed to be deleterious in several studies[5,12,14,17].

An IL-10RB heterozygous mutation was detected in one patient (patient 5) (Table 1 and Figure 1). This c.G421A (p.E141K) (rs387907326) mutation was located in exon 4 and was also predicted as a deleterious mutation by SIFT and Polyphen 2. A nonsense mutation in the same site was detected in previous studies[11,18].

Candidate gene polymorphisms

After the sequence analysis of the coding regions of 10 candidate genes, we found that six patients (patient 4, 5, 6, 7, 8 and 9) had many IBD-associated single nucleotide polymorphisms (SNPs) in IL-10RA, IL-10RB, NOD2, and FUT2. The SNP loci in IL-10RA were rs22280554: c.G525A, p. P175P and rs22280555: c.A670G, p.I224V; the SNP locus in IL-10RB was rs2834167: c.A139G, p.K47E; the SNP locus in NOD2 was rs5743277: c.C2107T, p.R703C; and the SNP locus in FUT2 was rs1047781: c.A418T, p.I140F (Table 1).

In addition to the detected p.R117H heterozygous mutation in IL-10RA, patient 4 also had heterozygous SNPs in NOD2 and FUT2.

Patient 5 had a heterozygous p.E141K mutation (rs387907326) in IL-10RB and SNPs in IL-10RA, IL-10RB, and FUT2. The SNP loci in IL-10RA were rs22280554 and rs22280555. The homozygous SNP loci for IL-10RB were rs2834167. The SNP in FUT2 was heterozygous.

Patients 6 and 7 had SNPs in IL-10RA and FUT2. Patients 8 and 9 had SNPs in IL-10RB and FUT2.

Four patients did not show any IBD-associated variations in the coding regions of the 10 candidate genes.

There was no IBD-associated variation discovered in the coding regions of six genes: IL-10, IL-23R, GPR35, GPR65, TNFSF15, and ADAM30.

Clinical characteristics of VEO-IBD pediatric patients

Out of the 13 VEO-IBD pediatric patients in this study, ten were diagnosed with CD (M:F = 9:1) and three had UC (M:F = 1:2). The mean age of disease onset was 5.8 ± 9.7 mo (range: birth to 3 years of age). None of the parents of the patients had a consanguineous marriage. Patient 8 had a brother that died as a neonate because of repeated diarrhea after birth. There was no clear diagnosis made at that time. The clinical symptoms of the pediatric patients included repeated abdominal pain (13/13), diarrhea (11/13), mucus and bloody stool (11/13), failure to thrive (8/13), recurrent infection (7/13), and perianal fistulas and abscesses (5/13). The colonoscopic presentation of patients with causative mutations showed pancolitis, cobblestone-like changes in mucosa, and deep and large ulcers (Figure 2). All patients received immunosuppressive treatment with glucocorticoids, 6-mercaptopurine and/or infliximab, and thalidomide; however, varying therapeutic effects were observed. Two patient died from severe sepsis or intestinal failure, 2 patients showed no change, 4 patients showed a partial alleviation of symptoms, and 5 patients showed complete clinical remission (Table 2).

Figure 2.

Colonoscopic presentation of patients with causative mutations showed pancolitis, cobblestone-like changes in mucosa, and deep and large ulcers. A to E presents patient 1 to patient 5, respectively.

Table 2.

Clinical manifestations of very early-onset inflammatory bowel disease

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10	Patient 11	Patient 12	Patient 13
Gender	F	M	M	M	M	M	M	M	M	M	M	F	F
Age of onset (mo)	8	1	0.3	0.3	4	0.2	9	2	0.5	3	0.7	10	36
Height percentile	19%	1%	3%	1%	1%	1%	52%	1%	15%	1%	19%	16%	20%
Weight percentile	1%	1%	1%	1%	1%	20%	55%	13%	8%	15%	16%	60%	33%
Diarrhea (times/d)	> 10	7-8	> 10	10	5-10	5-6	7-8	2-4	7-8	No diarrhea	7-8	No diarrhea	2-3
Bloody stool	+	+	+	+	+	-	+	+	+	-	+	+	+
Infection	Sepsis	Pneumonia	No	Pneumonia, Clostridium difficile infection	Sepsis, oral candidiasis, fungemia, Clostridium difficile infection	Recurrent respiratory infection	No	No	No	Repeated fever of unknow origin	Oral candidiasis, gingivitis	No	No
Perianal lesion	Fistulae	No	No	Excrescence	Fistulae, abscess, excrescence	Fistulae, ulcer	No	No	No	No	Fistulae, abscess, excrescence	No	No
Clinical diagnosis	CD	CD	CD	CD	CD	CD	CD	CD	UC	CD	CD	UC	UC
Medication	GC, 6-MP	IFX, THD	GC, THD	GC, IFX1, THD	GC, IFX, THD	GC, IFX1	GC, IFX, MES	GC, IFX1, THD, 6-MP	GC, MES	GC, 6-MP, THD	GC, IFX, THD, 6-MP	MES	GC, MES
Clinical status	NR	PR	Died at 2 yr because of severe sepsis	PR	Died at 3 yr because of intestinal failure	NR	CR	PR	CR	CR	PR	CR	CR

¹Allergic to IFX. CD: Crohn's disease; UC: Ulcerative colitis; GC: Glucocorticoid; 6-MP: 6-mercaptopurine; IFX: Infliximab; THD: Thalidomide; MES: Mesalazine; NR: Non-remission; PR: Partial remission; CR: Complete remission.

Clinical characteristics of different genotypes

Based on the presence of causative mutations in IL-10RA and IL-10RB, 13 patients were divided into two groups for analysis (group 1: causative mutations in IL-10RA or IL-10RB; group 2: polymorphisms and no causative mutations). The five patients in group 1 were all diagnosed with CD (100%). Four of these patients had recurrent infections (80%), and three patients had perianal diseases (60%). In group 2 (eight patients), five patients were diagnosed with CD (62.5%), and the other three patients were diagnosed with UC (37.5%). There were only three (37.5%) and two (25%) patients that had recurrent infections and perianal diseases, respectively. Patients in group 1 had lower body weight percentile (1.0% vs 27.5%, P = 0.002) and hemoglobin concentrations (87.4 g/L vs 108.5 g/L, P = 0.040) when compared with group 2. Although patients in group 1 had a younger age of disease onset (2.7 mo), lower body height percentile (5.0%), and higher CRP (60.7 mg/L), there were no significant differences when compared with group 2 (Table 3).

Table 3.

Comparison of features between patients with mutations and polymorphisms

	Group 1	Group 2
Size of sample	5	8
Age of onset (mo)	2.7	7.7
Height percentile	5.0%	15.6%
Weight percentilea	1.0%	27.5%
WBC (× 10-9)	15.2	16.3
Hemoglobin (g/L)a	87.4	108.5
Platelets (× 10-9)	538.4	424.0
C reactive protein (mg/L)	60.7	35.9
ESR (mm/H)	32.2	16.6
TNFα (pg/mL)	44.5	51.6
Diagnosis of CD	100.0%	62.5%
Recurrent infection	80.0%	25.0%
Perianal disease	60.0%	25.0%

^aP < 0.05. All measurement data are expressed as mean. Group 1: Mutations in IL-10RA or IL-10RB; Group 2: Polymorphisms. Height and weight percentile was calculated according to WHO charts. WBC: White blood cell; ESR: Erythrocyte sedimentation rate; TNFα: Tumor necrosis factor alpha; CD: Crohn's disease.

DISCUSSION

The currently recognized pathogenetic mechanism of IBD is the involvement of many environmental triggers and genetic susceptibility that causes intestinal immune dysfunction. However, the influence of genes are likely more important than environmental factors for VEO-IBD patients with a disease onset prior to 6 years of age, especially for patients with an infantile onset prior to 1 year of age[19]. GWAS studies suggested that SNPs of IL-10 and STAT3 were associated with IBD[20-23]. Previous studies confirmed that IL-10 or IL-10 receptor gene knockout mice had severe chronic inflammation of the intestinal tract[24]. IL-10 forms a complex with two molecules of IL-10R1 and two molecules of IL-10R2 to activate Janus kinase 1 (Jak1) and tyrosine kinase 2 (Tyk2). This activation results in the phosphorylation of signal transducer and activator of transcription 3 (STAT3), which regulates the transcription of specific genes. Studies suggested that IL-10-mediated signals effectively reduced the number of Th17 cells and relieved intestinal inflammation in CD[25]. These data indicated that the anti-inflammatory IL-10 signaling pathway plays a critical role in the regulation of intestinal immune homeostasis.

Since Glocker et al[8] first reported in 2009 that gene mutations in IL-10RA and IL-10RB caused infantile onset IBD[8], studies have continuously reported mutations in IL-10, IL-10RA, and IL-10RB in patients with infantile onset IBD[9-12,18,26]. In these limited data, the majority of patients were Arabian or Caucasian and the offspring of a consanguineous marriage. There are few reports on the Han Chinese population, which included only three pediatric patients to date[13,14].

In this study, we used high-throughput next generation sequencing technology to sequence 10 IBD-associated genes, IL-10, IL-10RA, IL-10RB, NOD2, FUT2, IL-23R, GPR35, GPR65, TNFSF15, and ADAM30, in 13 Han Chinese children diagnosed with VEO-IBD. A total of four mutations were discovered in IL-10RA, including two novel mutations. There was one mutation in IL-10RB. These pathogenic mutations were found in five patients, which accounted for 38.5% of all VEO-IBD cases. Among these patients, one had an IL-10RA homozygous mutation, two had IL-10RA compound heterozygous mutations, one had an IL-10RA heterozygous mutation, and one had an IL-10RB heterozygous mutation. All IL-10RA mutations were in exon 3, and c.C301T (p.R101W) showed the highest frequency. The c.C301T (p.R101W) and c.G350A (p.R117H) mutations in IL-10RA were previously reported in similar pediatric patients. These mutations may disrupt signal transduction after activation of the IL-10 receptor; therefore, STAT3 is not phosphorylated and intractable inflammatory reactions in the intestinal tract of pediatric patients develop[5,12]. The two novel mutations in IL-10RA discovered in this study were c.A191G (p.Y64C) and c.T299G (p.V100G). Because of condition limitations, we did not perform functional studies on these mutations. However, the SIFT prediction results for these two mutations were deleterious (scores of 0 and 0.002, respectively), and the Polyphen 2 prediction results were probably damaging (both scores were 1.000). These predictions suggest that these two mutations are pathogenic. According to the recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[27], these two mutations were defined as pathological supporting. Therefore, we speculate that these two novel mutations individually formed compound heterozygotes with the c.C301T (p.R101W) mutation to cause the disease symptoms observed in patients 2 and 3.

Previous analyses showed that the colitis caused by gene mutations in IL-10 and its receptor exhibited an autosomal recessive inheritance pattern. In the current study, patients 4 and 5 were carriers of heterozygous mutations in IL-10RA and IL-10RB, respectively. The c.G350A (p.R117H) mutation in IL-10RA carried by patient 4 was a pathogenic mutation[5,12,17]. The c.G421A (p.E141K) mutation in IL-10RB carried by patient 5 may affect protein function as predicted by SIFT (score = 0.026) and Polyphen 2 (score = 0.946). However, the clinical presentation of these two patients was similar to the symptoms of patients with other IL-10 receptor mutations: disease onset within 1 year of age, the presence of perianal diseases and recurrent infection, and resistance to conventional medication treatment. Based on currently available knowledge, there are at least 50 single-gene genetic conditions that induce IBD-like diseases, and the majority of conditions are related to immunodeficiency[4,6]. Therefore, the two patients that did not conform to a Mendelian genetic pattern might also carry abnormal sites on other genes that cause the disease symptoms. In addition to carrying a pathogenic mutation in IL-10RA, patient 4 also had a non-synonymous SNP (nsSNP): rs5743277 in NOD2. SIFT prediction results suggest that the nsSNP is deleterious (score = 0), and the Polyphen 2 prediction results suggest the nsSNP is probably damaging (score = 0.999). This polymorphism was already present in the HGMD database and has been considered to cause susceptibility to CD[28]. Patient 5 had a similar condition. In addition to carrying an IL-10RB mutation, patient 5 also had multiple polymorphisms: rs22280554 (homozygous) and rs22280555 (homozygous) in IL-10RA, rs2834167 (homozygous) in IL-10RB, and rs1047781 (heterozygous) in FUT2. There are previous reports on the pathogenicity of these SNPs. For example, Galatola et al[29] reported that the heterozygous rs2834167 in IL-10RB and the heterozygous mutation in the promoter region of IL-10RA caused the development of UC in an 18-month-old patient. Although rs22280554 did not cause a change in the amino acid sequence of IL-10R1, a study by Moran et al[30] showed that rs22280554 and rs2228055 in IL-10RA may increase the risk for VEO-IBD, especially VEO-UC. Furthermore, in the Han Chinese population, the rs1047781 polymorphism in FUT2 may increase the risk for CD development[31]. The above SNPs were also detected in four patients in this study. Therefore, their disease development may be due to “trans-heterzygous”: the collective effects of a variety of detected mutations. Another possible cause is that the pathogenic genes were not detected in this study.

When genotypes and phenotypes were combined for analyses, the results showed that the disease phenotype in patients with mutations were more severe. The age of disease onset was earlier, the patients were more likely to have combined recurrent infections and perianal diseases, their body weight and height were low, anemia was more severe, inflammatory indicators were high, and the prognosis was much poorer. These results are in accordance with previous studies[5,8-14,18,32]. However, the sample size of this study was small, and significant differences were only found in body weight and hemoglobin parameters. Because of the influence of cultural ideas, family members find difficulty in accepting an ileostomy as a disease treatment. Past literature reported that pediatric patients with IL-10RA and IL-10RB mutations could be cured through hematopoietic stem cell transplantation[4,6,8,17]; therefore, some patients are waiting for a donor match.

In this study, we found that mutations in IL-10RA and IL-10RB were more common in Han Chinese VEO-IBD patients and accounted for 38.5% of all VEO-IBD cases. The high percentage is probably due to the small number of patients in the cohort as most of our patients who were referred by other clinical IBD centers were very ill. There was a selection bias. Because VEO-IBD is relatively rare, multi-center studies on the relationship between genotypes and phenotypes in VEO-IBD patients in China are necessary. The implementation of hematopoietic stem cell transplantation therapy is the focus in research agenda.

COMMENTS

Background

Very early-onset inflammatory bowel disease (VEO-IBD) may have stronger genetic contribution. Recently, a few studies on genetic defects in the IL-10 signaling pathway have provided new insights into IBD, especially in VEO-IBD. Furthermore, a lot of genes associated with IBD were identified, such as NOD2, FUT2, IL-23R, GPR35, GPR65, TNFSF15, and ADAM30. Because of different genetic background, this study was set to disclose whether mutations in these genes contributed to VEO-IBD in Chinese children.

Research frontiers

In addition to the polygenic variants associated with IBD, there are rare monogenic disorders, including many immunodeficiencies that can present with IBD-like intestinal inflammation, especially in early life.

Innovations and breakthroughs

To our knowledge, this is the first cohort study to apply NGS in 13 Chinese pediatric patients with VEO-IBD to discover gene variations in these children. The result revealed that IL-10RA and IL-10RB mutations were common in Chinese VEO-IBD, especially in infantile IBD. These monogenic IBD patients had more severe clinical features.

Applications

According to the results of this study and previous studies of VEO-IBD, the authors suggest that screening for gene mutations in IL-10 signaling pathway is necessary.

Peer-review

The clinical study is focused on gene mutation analysis in VEO-IBD by NGS. The authors conclude that mutations in the IL-10 pathway are common in VEO-IBD.